Switch theme
Sign up to access all valuation multiples
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
2000
222
LTM Revenue $46.7M
LTM EBITDA -$70.5M
$3.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cellectis has a last 12-month revenue (LTM) of $46.7M and a last 12-month EBITDA of -$70.5M.
In the most recent fiscal year, Cellectis achieved revenue of $46.6M and an EBITDA of -$10.6M.
Cellectis expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cellectis valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $46.7M | XXX | $46.6M | XXX | XXX | XXX |
| Gross Profit | $46.7M | XXX | $36.3M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 78% | XXX | XXX | XXX |
| EBITDA | -$70.5M | XXX | -$10.6M | XXX | XXX | XXX |
| EBITDA Margin | -151% | XXX | -23% | XXX | XXX | XXX |
| EBIT | -$82.9M | XXX | -$66.9M | XXX | XXX | XXX |
| EBIT Margin | -177% | XXX | -143% | XXX | XXX | XXX |
| Net Profit | -$64.6M | XXX | -$41.3M | XXX | XXX | XXX |
| Net Margin | -138% | XXX | -89% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Cellectis's stock price is EUR 1 (or $2).
Cellectis has current market cap of EUR 136M (or $153M), and EV of EUR 2.7M (or $3.1M).
See Cellectis trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.1M | $153M | XXX | XXX | XXX | XXX | $-0.64 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Cellectis has market cap of $153M and EV of $3.1M.
Cellectis's trades at 0.1x EV/Revenue multiple, and -0.3x EV/EBITDA.
Equity research analysts estimate Cellectis's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cellectis has a P/E ratio of -2.4x.
See valuation multiples for Cellectis and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $153M | XXX | $153M | XXX | XXX | XXX |
| EV (current) | $3.1M | XXX | $3.1M | XXX | XXX | XXX |
| EV/Revenue | 0.1x | XXX | 0.1x | XXX | XXX | XXX |
| EV/EBITDA | -0.0x | XXX | -0.3x | XXX | XXX | XXX |
| EV/EBIT | -0.0x | XXX | -0.0x | XXX | XXX | XXX |
| EV/Gross Profit | 0.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.4x | XXX | -3.7x | XXX | XXX | XXX |
| EV/FCF | -0.1x | XXX | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCellectis's last 12 month revenue growth is -2%
Cellectis's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
Cellectis's rule of 40 is -12272% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cellectis's rule of X is -157% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Cellectis and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -2% | XXX | 6% | XXX | XXX | XXX |
| EBITDA Margin | -151% | XXX | -23% | XXX | XXX | XXX |
| EBITDA Growth | 31% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -12272% | XXX | -25% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -157% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 218% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 221% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cellectis acquired XXX companies to date.
Last acquisition by Cellectis was XXXXXXXX, XXXXX XXXXX XXXXXX . Cellectis acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Cellectis founded? | Cellectis was founded in 2000. |
| Where is Cellectis headquartered? | Cellectis is headquartered in France. |
| How many employees does Cellectis have? | As of today, Cellectis has 222 employees. |
| Who is the CEO of Cellectis? | Cellectis's CEO is Dr. Andre Choulika, PhD. |
| Is Cellectis publicy listed? | Yes, Cellectis is a public company listed on PAR. |
| What is the stock symbol of Cellectis? | Cellectis trades under ALCLS ticker. |
| When did Cellectis go public? | Cellectis went public in 2007. |
| Who are competitors of Cellectis? | Similar companies to Cellectis include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Cellectis? | Cellectis's current market cap is $153M |
| What is the current revenue of Cellectis? | Cellectis's last 12 months revenue is $46.7M. |
| What is the current revenue growth of Cellectis? | Cellectis revenue growth (NTM/LTM) is -2%. |
| What is the current EV/Revenue multiple of Cellectis? | Current revenue multiple of Cellectis is 0.1x. |
| Is Cellectis profitable? | Yes, Cellectis is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cellectis? | Cellectis's last 12 months EBITDA is -$70.5M. |
| What is Cellectis's EBITDA margin? | Cellectis's last 12 months EBITDA margin is -151%. |
| What is the current EV/EBITDA multiple of Cellectis? | Current EBITDA multiple of Cellectis is -0.0x. |
| What is the current FCF of Cellectis? | Cellectis's last 12 months FCF is -$54.3M. |
| What is Cellectis's FCF margin? | Cellectis's last 12 months FCF margin is -116%. |
| What is the current EV/FCF multiple of Cellectis? | Current FCF multiple of Cellectis is -0.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
